Med. praxi. 2016;13(1):39-42 [Neurol. praxi. 2015;16(5):273-277]

New ways of administering injection drugs in relapsing multiple sclerosis

MUDr.Jiří Piťha
MS centrum při Neurologickém odděleni KZ a.s. &ndash, Nemocnice Teplice o. z., Teplice

The review article provides information on new ways of administering parenteral drugs indicated in the treatment of multiple sclerosis or clinically isolated syndrome. The issues covered include reducing the frequency of administration and increasing the dose, switching from intravenous or intramuscular to subcutaneous administration, or altering the active molecule. The new drugs have the same efficacy as the original ones, while the rate of adverse effects is maintained or even reduced.

Keywords: new forms of injectable drugs, multiple sclerosis

Published: March 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Piťha J. New ways of administering injection drugs in relapsing multiple sclerosis. Med. praxi. 2016;13(1):39-42.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arnold DL, Calabresi PA, Kieseier BC, Sheikh SI, Deykin A, Zhu Y, Liu S, You X, Sperling B, Hung S. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurol. 2014; 14: 240. Go to original source... Go to PubMed...
    2. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A. ADVANCE Study Investigators. Pegylated interferon ?-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014; 13: 657-665. Go to original source... Go to PubMed...
    3. Caporro M, Disanto G, Gobbi C, Zecca C. Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment. Patient Prefer Adherence. 2014; 21: 1123-1134. Go to original source...
    4. Cocco E, Marrosu MG. Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Ther Clin Risk Manag. 2015; 11: 759-766. Go to original source... Go to PubMed...
    5. Cohen BA, Coyle PK, Leist T, Oleen-Burkey MA, Schwartz M, Zwibel H. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse. Mult Scler Relat Disord. 2015; 4: 75-82. Go to original source... Go to PubMed...
    6. Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Neurology 2007; 68: 939-944. Go to original source... Go to PubMed...
    7. Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol. 2011; 69: 75-82. Go to original source... Go to PubMed...
    8. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M. PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 374: 1503-1511. Go to original source... Go to PubMed...
    9. Johnson KP, Brooks BR, Ford CC, Goodman AD, Lisak RP, Myers LW, Pruitt AA, Rizzo MA, Rose JW, Weiner LP, Wolinsky JS. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult Scler. 2003; 9: 585-591. Go to original source... Go to PubMed...
    10. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013; 73: 705-713. Go to original source... Go to PubMed...
    11. Trojano M, Ramió-Torrent? L, Grimaldi LME, Lubetzki C, Schippling S, Evans K, Gheuens S, Muralidharan K, Mikol D. A randomized, blinded, parallel-group phase-2 study exploring the efficacy, safety, and tolerability of multiple natalizumab dosing regimens in patients with relapsing multiple sclerosis (REFINE). Congress of European Academy of Neurology (EAN) 2015. Abstract O1217.
    12. Wolinsky JS, BorresenTE, Dietrich DW, Gilder B, Sidi Y, Knappertz V, Kolodny S. GLACIER: Open-label, randomized safety/tolerability study of glatiramer acetate 40 mg/mL three times weekly versus 20mg/mL daily in RRMS. Neurology 2014; 82(Suppl. 10): S31.002.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.